In8bio Inc (INAB) - Total Liabilities
Based on the latest financial reports, In8bio Inc (INAB) has total liabilities worth $3.58 Million USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore In8bio Inc (INAB) cash flow conversion to assess how effectively this company generates cash.
In8bio Inc - Total Liabilities Trend (2018–2024)
This chart illustrates how In8bio Inc's total liabilities have evolved over time, based on quarterly financial data. See INAB total equity for net asset value and shareholders' equity analysis.
In8bio Inc Competitors by Total Liabilities
The table below lists competitors of In8bio Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Phapros Tbk PT
JK:PEHA
|
Indonesia | Rp1.06 Trillion |
|
West International AB
ST:WPAY
|
Sweden | Skr40.13 Million |
|
Idomoo Ltd
TA:IDMO
|
Israel | ILA15.83 Million |
|
Cheetah Holdings Bhd
KLSE:7209
|
Malaysia | RM27.93 Million |
|
Asia Sejahtera Mina Tbk
JK:AGAR
|
Indonesia | Rp77.18 Billion |
|
Winhitech Co Ltd
KQ:192390
|
Korea | ₩77.68 Billion |
|
Sapura Resources Bhd
KLSE:4596
|
Malaysia | RM571.97 Million |
|
RPCG Public Company Limited
BK:RPC
|
Thailand | ฿5.21 Billion |
Liability Composition Analysis (2018–2024)
This chart breaks down In8bio Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see market cap of In8bio Inc.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.91 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how In8bio Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for In8bio Inc (2018–2024)
The table below shows the annual total liabilities of In8bio Inc from 2018 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $6.47 Million | -26.29% |
| 2023-12-31 | $8.77 Million | -14.89% |
| 2022-12-31 | $10.31 Million | +155.12% |
| 2021-12-31 | $4.04 Million | +56.04% |
| 2020-12-31 | $2.59 Million | +75.41% |
| 2019-12-31 | $1.48 Million | +18.27% |
| 2018-12-31 | $1.25 Million | -- |
About In8bio Inc
IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candid… Read more